Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.

Menopausal hormone therapy (HT) is typically withheld from breast cancer survivors because of concerns about risk for recurrence. Our objectives were to estimate the effects of HT on recurrence in breast cancer survivors and to examine the reliability of these estimates.